Kornimate/medical-research-clean huggingface dataset:
carotis cft in prediction of hypotension

Conditions: Flow Time; Carotid Doppler Ultrasound; Hypotension; Anesthesia; Elderly

Summary: the aim of our study is to determine the predictive value of pre-anesthesia ftc for hypotension that may develop after general anesthesia induction in patients over 65 years of age and to investigate the correlation between pre-anesthesia ftc and the magnitude of the maximum decrease in systolic blood pressure from the pre-anaesthetic value.

the ftc value of the patients to be included in the study will be measured by ultrasonography 10 minutes before the induction of anesthesia.after the measurement, the patients will be monitored with 3-lead electrocardiography, pulse oximetry and noninvasive blood pressure in the operating room. before induction of general anesthesia, systolic blood pressure (sbp), diastolic blood pressure (dbp), mean blood pressure (map), oxygen saturation and heart rate will measured for 3 minutes at 1-minute intervals. induction of anesthesia with 1-2 mg/kg propofol, muscle relaxation will be achieved with 0.6 mg/kg intravenous rocuronium. during mask ventilation, 1-2% concentration of sevoflurane and 50-50% oxygen-nitrous oxide will be used. after the anesthesia induction, sbp, dbp, map, oxygen saturation and heart rate will be measured for 3 minutes at 1-minute intervals. hypotension; defined as a 30% reduction in sbp or a 20% reduction in map, or an absolute sbp below 90 mm hg and map below 65 mm hg within 3 minutes of induction of general anesthesia.intravenous (iv) noradrenaline and/or iv crystalloid will be used in the treatment of hypotension.

Eligibility criteria:
inclusion criteria: * \>65 years old * undergoing elective surgery under general anesthesia exclusion criteria: * mean arterial pressure \< 70 mmhg * systolic blood pressure \> 180 mmhg * diastolic blood pressure \> 110 mmhg * \< 65 years old * carotid artery stenosis \> 50% * asa \> 3 * left ventricle ejection fraction \< 40% * severe peripheral vascular disease * implanted pacemacer * autonomic nervous system disorders * heart valve disease * chronic kidney disease * emergency surgery
comparison of levothyroxine formulation in hypothyroid patients with enteral feeding

Conditions: Hypothyroidism

Summary: the purpose of this study is to test a liquid levothyroxine formula and examine if it will lead to improvement in management of thyroid function and if it improves hypothyroid symptoms that patients experience.

patients who require enteral nutrition through an enteral feeding tube and have hypothyroidism often struggle with the management of hypothyroidism. hypothyroidism usually requires lifelong treatment except in some cases. it has been clinically observed the traditional management of hypothyroidism is to crush the tablet and administer the medical through the enteral nutrition tube and hold the feeds for one hour. however, management of the hormonal profile has been noted to have variable results with this method. limited data is available about the effectiveness of levothyroxine liquid formulation in outpatients' dependent on enteral feeding tubes for administration. therefore, we propose a study to assess if daily treatment of, tirosint-sol (liquid levothyroxine, ibsa pharma inc.), will improve thyroid function tests in individuals requiring enteral nutrition and are hypothyroid in a prospective, randomized study in a population requiring enteral nutrition. we hypothesize that tirosint-sol will lead to improvement in management in their thyroid function tests resulting in possible improvement in hypothyroid symptoms experienced by the patients. this will be a randomized controlled trial. the study will be conducted in patients who have uncontrolled hypothyroidism on levothyroxine therapy. these patients will also be dependent on enteral nutrition and medication administration through the gastrostomy tube. the participants will be followed at ucla enteral nutrition clinic. participants will be randomized 1:1 to either continue current management with the same dose or to dose equivalent liquid levothyroxine. at baseline (week 0) and week 6-8, tsh and thyroid function tests will be performed. in addition, medical history and physical, body weight, hr, blood pressure, nutritional intake by a registered dietitian will be done at each visit.

Eligibility criteria:
inclusion criteria: * adults age 18 years old or older * g-tube/g-j tube dependent for medication administration * hypothyroid patients on levothyroxine tablet * tsh\>5 on levothyroxine exclusion criteria: * j-tube * unstable cardiac condition * unstable gastrointestinal condition * unable to reliably administer medication * screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator. * in the opinion of the study investigator, any subject who demonstrate a risk of non-compliance with study procedure, or one who cannot read, understand or complete study - related materials.

Keywords: levothyroxine enteral nutrition gastrostomy tube
endoscopic grading of intestinal metaplasia

Conditions: Narrow-band Imaging; Magnifying Endoscopy; Gastric Intestinal Metaplasia

Summary: long-term helicobacter pylori infection causes premalignant gastric conditions, such as atrophic gastritis and intestinal metaplasia. image-enhanced endoscopy techniques such as narrow-band imaging (nbi) and magnifying endoscopy improve the diagnosis of gastric intestinal metaplasia (gim). however, there are no comparative data on the utility of nbi and magnifying endoscopy for diagnosing gim.

this study aims to evaluate the diagnostic performance of nbi and magnifying endoscopy for gim in a country with high risk of gastric premalignant lesions.

Eligibility criteria:
inclusion criteria: * gastroscopy can be performed * pathological analysis can be performed for analysis of gastric atrophy and intestinal metaplasia exclusion criteria: * age \ 80 years * anemia (serum hemoglobin level \< 10 g/dl) * severe systemic disease * advanced chronic liver disease * use of certain medications, including proton pump inhibitors, h2-receptor antagonists, or antibiotics * history of h. pylori eradication * history of gastric surgery * recent history of upper gastrointestinal bleeding
cerebral hemodynamics during early verticalization after (successful) thrombectomy poststroke

Conditions: Stroke; Healthy

Summary: this is a proof-of-concept study with a prospective observational design, where the association between progressive levels of verticalization and cerebral blood flow velocity (ultrasound) in subacute stroke patients and healthy subjects will be investigated.


Eligibility criteria:
inclusion criteria: * first-ever ischemic stroke in the territory of the middle cerebral artery (mca) * ≤12 hours after mechanical thrombectomy * conscious * hemodynamically stable * 18 years or older * informed consent of the patient and/ or legal representative exclusion criteria: * verticalization not allowed according to treating physician * known pre-stroke disease affecting cerebral blood flow * temporal bone windows insufficient to enable ultrasound penetration * intubation anticipated or occurred * venous thromboembolism * symptomatic intracranial hemorrhage
prospective decision impact trial of kidneyintelx

Conditions: Diabetic Kidney Disease; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Chronic Kidney Disease, Stage 3 (Moderate)

Summary: the current trial is designed to evaluate how the results of kidneyintelx test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.


Eligibility criteria:
inclusion criteria: * 23 years of age or older. * clinical history of confirmed type 2 diabetes. * evidence of dkd stages 1-3: * baseline egfr of 30-59 ml/min/1.73m2 (confirmed 3 months apart with at least one value within 1 year prior to enrollment) * individuals with egfr ≥60 ml/min/1.73m2 and albuminuria (uacr ≥30mg/g) * all patients will have a hba1c, egfr, urine albumin and urine creatinine, egfr, available from within 12 months of enrollment (to be obtained if not clinically available prior). * the subject must be able to comprehend and sign an approved informed consent form and other applicable study documents. exclusion criteria: * patients with egfr \<30 or ≥ 60 ml/min/1.73m2 without albuminuria. * patients with esrd or on renal recovery treatments at time of enrollment. * patients who are pregnant at the time of enrollment. * patients who are currently hospitalized. * patients who are currently on enbrel.
prevention of hypocalcemia in patients undergoing total thyroidectomy plus central neck dissection

Conditions: Hypocalcemia

Summary: the increased risk of hypocalcemia following total thyroidectomy plus central neck dissection can be minimized by routine administration of oral calcium and vitamin d supplements during the early postoperative period.

of patients with differentiated papillary thyroid carcinoma, group d underwent total thyroidectomy alone and groups a-c underwent total thyroidectomy plus cnd. the latter were randomized to oral calcium (3 g/day) plus vitamin d (1 mcg/day) (group a, n = 49), calcium alone (group b, n = 49), or no supplements (group c, n = 50). hypocalcemic symptoms, serum calcium, and parathyroid hormone (pth) levels were compared among the groups.

Eligibility criteria:
inclusion criteria: * differentiated papillary thyroid carcinoma * undergoing total thyroidectomy plus central neck dissection exclusion criteria: * previous thyroid or neck surgery * patients with parathyroid diseases * other thyroid malignancies * early loss of follow-up without proper evaluation of postoperative serum calcium levels and symptoms

Keywords: total thyroidectomy cnd hypocalcemia calcium vitamin d
psma guided approach for biochemical relapse after prostatectomy-psiche

Conditions: Prostate Cancer; Biochemical Relapse Fo Malignant Neoplasm of Prostate; Prostate Adenocarcinoma; Prostate Cancer Recurrent

Summary: this observational study was designed to evaluate progression free survival after psma-pet/ct based salvage approach for patients affected by biochemical relapse after radical prostatectomy.

this is a prospective observational multicenter study including patients treated with upfront radical prostatectomy +/- postoperative prostate bed radiotherapy, with histological result of prostate adenocarcinoma, affected by biochemical relapse (defined as psa\>/= 0.2 ng/ml) with a psa at recurrence \</=1 ng/ml. patients will be staged with centralized 68 ga- psma pet/ct and treated with a pre-defined approach based on 68 ga-psma pet/ct findings. the predefined approach will consist in the following flowchart: 1. in negative 68ga-psma pet/ct or positive findings within prostate bed: prostate bed rt 2. in 68ga-psma pet/ct detecting pelvic nodal recurrence amenable with stereotactic body radiation therapy (sbrt) on all sites of disease: sbrt to all positive nodal disease. 3. in abdominal nodal or bone oligometastatic disease amenable with stereotactic body radiation therapy (sbrt) on all sites of disease: sbrt on all sites of disease 4. in abdominal nodal or bone metastatic disease (\>3 lesions or non-amenable with sbrt) and/or visceral disease: adt+/-other systemic therapies available for metastatic hormone sensitive pca at physician discretion.

Eligibility criteria:
inclusion criteria: * signed informed consent * age \>18 * patient suitable for 68ga-psma pet/ct re-staging according to clinical practice (previous radical prostatectomy with histological result of prostate adenocarcinoma +/- postoperative prostate bed radiotherapy (adjuvant or salvage setting), with a biochemical relapse defined as a psa \> 0.2 and \<1 exclusion criteria: * adt administration within 6 months from study enrollment * persistent elevation of psa after rp measured within 16 weeks from surgery (\> 0.1 ng/ml)

Keywords: psma 68ga-psma pet/ct pet/ct biochemical relapse micro-rna sbrt radiotherapy
guided biopsy for mapping prostate cancer

Conditions: Prostate Cancer

Summary: evaluate the accuracy of hit guided biopsies for mapping tumor foci with men undergoing prostatectomy.

the objective of this study is to determine the accuracy of hit (hybrid imaging technology) guided biopsies for mapping tumor foci with men undergoing prostatectomy. using a prostate hybrid imaging technology (hit) which fuses a previously obtained endorectal mr image to transrectal ultrasound (trus) image to allow identification and biopsy of tumors by mr imaging in real time. we hypothesis that hit guided biopsies will accurately localize the foci of prostate cancer.

Eligibility criteria:
inclusion criteria: * patients must have histologically confirmed diagnosis of prostate cancer * patients must have elected to undergo radical prostatectomy using an open, laparoscopic or robotic approach * patients must be at least 18 years of age and able to provide written informed consent. * no history of radiotherapy, chemotherapy or hormone therapy within 6 months of surgery * primary tumor must be amenable to surgical removal for curative intent * patients must have ecog-performance status 0 or 1 (appendix ii) * patients must have no history of rectal or anal disease. * patients must have adequate organ function as defined by the following criteria: * serum aspartate transaminase (ast; serum glutamic oxaloacetic transaminase \[sgot\]) and serum alanine transaminase (alt; serum glutamic pyruvic transaminase \[sgpt\])≤2.5x local laboratory upper limit of normal (uln), or ast and alt ≤5x uln if liver function abnormalities are due to underlying malignancy * total serum bilirubin ≤1.5 x uln * absolute neutrophil count(anc)≥1,500/microl * platelets≥loo,ooo/microl * hemoglobin≥9.0 g/dl * serum calcium≤10.2mg/dl (correct for low albumin if necessary; calcium + (normal albumin - serum albumin)x 0.8) * patients must have serum creatinine\ 40ml/min(crcl= wt(kg)x(140-age)\*/72xcr. level,\*female x 0.85) inclusion of minorities: * members of all races and ethnic groups are eligible for this trial. women and children are not eligible since prostate cancer is not diagnosed in these groups.

Keywords: prostate cancer prostatectomy
safe d3 right hemicolectomy for cancer through multidetector computed tomography (mdct) angio

Conditions: Colon Cancer

Summary: when performing a resection of the right colon due to cancer one aims not only to remove the tumor bearing bowel segment, but also lymph nodes draining the affected area. these lymph nodes are located along the arteries supplying the right colon. through using a preoperative ct scan which can map these arteries very precisely one can ligate these vessels closer to their origin and thus remove more lymph nodes which may potentially harbor cancer cells. this study aims to compare patients operated more radically through use of preoperative ct which maps the mentioned arteries with patients operated in the standard way.

the norwegian gastrointestinal cancer group has recommended d3 resection as the standard operative technique for colon cancer. d3 resection implies ligation of the blood vessels at their origin. there is evidence that the recurrence free period and survival improves with the number of lymph nodes harvested at surgery. however, the current practice in norway, while performing right hemicolectomy for cancer is to ligate the feeding vessels for the right colon on the right hand side of the superior mesenteric vein (smv). significant arterial stumps have been demonstrated in patients operated for right colon cancer with this technique (right colic artery and ileocolic artery vascular stumps with an average length of 3.5 cm and 2.5 cm, respectively). this leaves reason to believe that a certain number of central lymph nodes remain after the procedure. the complex anatomical relationship between the right colic artery and ileocolic artery with the superior mesenteric vein make d3 resection demanding, especially if the right colic artery lies posterior to the smv. these relationships are investigated in detail in postmortem anatomical studies. these studies show that the right colic artery lies most often anterior to the smv, while the ileocolic artery lies most often posterior to the smv. data has also been provided that a ct angiography can verify these relations as well as postmortem anatomical studies in living patients, thus allowing the surgeon to be aware of them prior to surgery. this could prove to be crucial in planning the procedure.

Eligibility criteria:
inclusion criteria: * patients with histo-pathologically verified adeno-carcinoma of the right colon * patients under the age of 75 * patients medically cleared by anesthesiologist for general anesthesia * signed informed consent form exclusion criteria: * patients with recurrent cancer after previous surgery * patients with distant metastasis * patients who are not medically cleared to undergo anesthesia * patients who do not sign the informed consent form

Keywords: d3 resection right colectomy mdct angiography lymphadenectomy safe right colon preoperative
an in-situ detection for microrna

Conditions: Breast Cancer

Summary: we designed a new in-site detection method for microrna in the serum of patients with breast cancer.


Eligibility criteria:
inclusion criteria: healthy without serious diseases - exclusion criteria: * situations that may affect the results
a study of the effectiveness and safety of amg 386 and sorafenib to treat advanced or inoperable hepatocellular cancer

Conditions: Advanced Hepatocellular Carcinoma; Inoperable Hepatocellular Carcinoma

Summary: the purpose of this study is to determine whether amg 386, in combination with sorafenib, is effective in the treatment of advanced or inoperable hepatocellular cancer in subjects who have not received any prior systemic therapy except surgery or locoregional therapy. disease status and disease progression will be assessed every 8 weeks. subjects will remain on treatment until: progressive disease by recist criteria; clinical progression; death or loss to follow-up; or withdrawal of informed consent.

the primary objective is to evaluate the efficacy of amg 386 in combination with sorafenib as measured by the progression free survival (pfs) rate at 4 months in subjects with advanced or inoperable hepatocellular carcinoma (hcc).

Eligibility criteria:
inclusion criteria: * histologically confirmed advanced or inoperable hcc * child-pugh a liver function score * measurable disease with at least one unidimensionally measurable lesion per recist 1.0 guidelines with modifications * adequate organ and hematological function * men or women greater than or equal to 18 years old * eastern cooperative oncology group (ecog) performance status of 2 or less exclusion criteria: * subject is eligible for a liver transplant per investigators discretion * any previous systemic chemotherapy for hcc * history of arterial or venous thromboembolism within 12 months prior to enrollment * history of clinically significant bleeding within 6 months prior to enrollment * history of central nervous system metastases * clinically significant cardiovascular disease within 12 months * uncontrolled hypertension * subjects with a history of prior malignancy
real world study of peg-rhg-csf in prevention of chemotherapy-induced neutropenia

Conditions: Chemotherapy-induced Neutropenia; Myelosuppression

Summary: the aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of peg-rhg-csf in preventing chemotherapy-induced neutropenia(cin) of cancer patients in the real world.1000 patients with non-myeloid malignancy who is planned to receive peg-rhg-csf for cin prevention and 500 patients with non-myeloid malignancy who is planned to receive rhg-csf for cin prevention or treatment were prospectively recruited.the primary outcome was cost-effectiveness and second outcome was febrile neutropenia,the incidence and duration of grade iv neutropenia,chemotherapy delay,incidence of reduced dose of chemotherapy and relative dose intensity of chemotherapy.


Eligibility criteria:
inclusion criteria: 1. patients' age≥18 years old, male or female 2. diagnosis of non-myeloid malignant solid tumors 3. patients are planned to perform chemotherapy and preventive use the peg-rhg-csf or preventive or therapeutic use of rhg-csf after chemotherapy 4. patients' mental status are well, could understand the study and willing to participate the study, sign the informed consent form 5. the investigator believes that patients can benefit from this study exclusion criteria: 1. patients who have been confirmed to be allergic to jinyouli® or rhg-csf or its excipients 2. pregnant or lactating women and women who plan to be pregnant during clinical observation 3. other patients that the doctor believe not suitable for inclusion

Keywords: peg-rhg-csf pegfilgrastim
psoriatic disease and related manifestations; real world evidence in brazilian secukinumab environment

Conditions: Psoriasis (PsO); Psoriatic Arthritis (PsA)

Summary: this was a retrospective observational study that relied on data extracted from patient chart review at the participating sites. at least 12 months of patient data was verified, comprising at least 6 months (pre-period) and 6 months (post-period) after secukinumab initiation (index date). all data extracted from patient charts was entered into an electronic case report form (ecrf), specifically designed to capture all variables needed for the study data analysis.


Eligibility criteria:
inclusion criteria: * adult patients aged ≥18 years at index date. * patients with pso diagnosed with psa (concomitant or sequentially), either by a rheumatologist or dermatologist, at least 6 months prior to initiation of secukinumab treatment. * continuously treated with secukinumab for at least 24 weeks (6 months) after index date. * medical history available from at least the one-year study period (at least 6 months previous to the start of secukinumab treatment and at least 6 months after). exclusion criteria: * patients who interrupted secukinumab treatment for 3 or more months during the 6-month period (post-period) for any cause. * patients known to be participating in an interventional study at any point of the one-year study period.
china peace 5r-hf study

Conditions: Heart Failure

Summary: this study will use a two-stage random sampling design to create a nationally representative sample of patients with heart failure (hf) in china. the investigators sought to describe the clinical profiles, to assess treatment patterns and in-hospital outcomes for hf, and to identify targets for care quality improvement.

this study will use a two-stage random sampling design to create a nationally representative sample in china, and randomly sample patients with hf as a primary diagnosis, and were admitted to hospital from january 1st, 2015 to december 31st, 2015. the sample size is estimated to be 10,000. the investigators will collect photocopies of the sampled medical records and centrally abstract detailed information, which included demographic characteristics, medical history, clinical features, diagnostic tests, in-hospital procedures, lab tests, treatments, and in-hospital outcomes. data abstraction quality was monitored by random auditing of 5% of the medical records, with overall variable accuracy exceeding 98%. analyses will examine patient characteristics, diagnostic testing patterns, in-hospital treatments, in-hospital outcomes, and variation in results across regions and hospitals. practical guidelines, quality evaluative system, and risk model will be established based on the findings, to improve patient outcomes for hf in the future.

Eligibility criteria:
inclusion criteria: * patients with heart failure as the primary reason for hospitalization, including both new-onset hf or decompensation of chronic hf。 * hospitalized during january 1st, 2015 to december 31st, 2015 * aged 18 years or above exclusion criteria: * none

Keywords: heart failure, retrospective